Regulatory

Bulletin from the extraordinary general meeting in Ascelia Pharma AB

2021-04-13
Download

Today, on 13 April 2021, an extraordinary general meeting was held in Ascelia Pharma AB. A sum-mary of the adopted resolutions follows below. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the meeting was held only by advance voting (postal vote) in accordance with temporary legislation.

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Resolution on approval of the board of directors’ resolution on directed issue of shares
The meeting resolved to approve the board of directors’ resolution of 17 March 2021 to increase the company’s share capital with not more than SEK 5,000,000 through the issue of not more than 5,000,000 ordinary shares. Through the directed issue of shares, the company will receive SEK 200 million before transaction costs. The net proceeds are intended to be used for (i) financing the Phase 2 study for the oral chemotherapy drug candidate Oncoral, (ii) accelerating activities towards the commercialization of the diagnostic drug Mangoral, currently in an ongoing Phase III study and (iii) general corporate purposes.

2021-05-05

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021

Today, on 5 May 2021, the annual general meeting was held in Ascelia Pharma AB. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual general meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.
2021-04-30

Number of shares and votes in Ascelia Pharma AB

2021-04-15

Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm

The board of directors of Ascelia Pharma AB (”Ascelia Pharma” or the “Company”) has, as a result of the directed issue of 5,000,000 shares to a number of Swedish and international institutional investors, that was published on 17 March 2021 and approved by the extraordinary general meeting on 13 April 2021, prepared a prospectus for admission to trading of the new shares on Nasdaq Stockholm. The prospectus does not constitute an offering ...